M2 Pharma - Therapy Areas

PerkinElmer Expands KRAS Oncology Drug Discovery Assays with New Ready-to-Use AlphaLISA Kits

29 July 2021 - - US-based life science company PerkinElmer, Inc has launched four new ready-to-use AlphaLISA KRAS kits, designed to help scientists better understand complex KRAS protein structur...

First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa and Chemotherapy

29 July 2021 - - The first patient has been dosed with zanidatamab in combination with Tukysa (tucatinib) and capecitabine in a new cohort of a Phase 1 trial for HER2-positive breast cancer patie...

Clarity Pharmaceuticals begins 64/67Cu SAR-bisPSMA theranostic clinical trial in US patients with metastatic castrate resistant prostate cancer

29 July 2021 - Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company, announced on Wednesday that it has started its 64/67Cu SAR-bisPSMA theranostic clinical trial in patients with met...

Transcenta Holding's TST001 receives US FDA Orphan Drug Designation

29 July 2021 - Transcenta Holding Limited, a China-based clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based ...

Immix Biopharma names new director

29 July 2021 - Immix Biopharma Inc, a US-based company involved in Tissue Specific Therapeutics for oncology and inflammation, announced on Wednesday that Jane Buchan, PhD is its new director.Dr Bucha...

ImmunityBio's Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a US Patent

28 July 2021 - - US-based immunotherapy company ImmunityBio, Inc has been granted a patent by the US Patent and Trademark Office for its proprietary NANT Cancer Vaccine (US Patent 11,071,774), the com...